Orserdu
EC approves Menarini Group’s Orserdu for breast cancer treatment
September 21, 2023Medical Communications European Commission, Oncology, Orserdu, breast cancer
The Menarini Group and its subsidiary Stemline Therapeutics have announced that the European Commission (EC) has approved Orserdu (elacestrant) as …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
